Cargando…

Discovery of New Microbial Collagenase Inhibitors

SIMPLE SUMMARY: Antimicrobial resistance is spreading globally, making healthcare specialists fear “a return to the dark age of medicine”. Great efforts are being made to develop new antimicrobials or to repurpose discontinued or shelved drugs to be used against resistant “superbugs”. Resistance occ...

Descripción completa

Detalles Bibliográficos
Autores principales: Nitulescu, Georgiana, Mihai, Dragos Paul, Zanfirescu, Anca, Stan, Miruna Silvia, Gradinaru, Daniela, Nitulescu, George Mihai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9781087/
https://www.ncbi.nlm.nih.gov/pubmed/36556479
http://dx.doi.org/10.3390/life12122114
_version_ 1784856987977121792
author Nitulescu, Georgiana
Mihai, Dragos Paul
Zanfirescu, Anca
Stan, Miruna Silvia
Gradinaru, Daniela
Nitulescu, George Mihai
author_facet Nitulescu, Georgiana
Mihai, Dragos Paul
Zanfirescu, Anca
Stan, Miruna Silvia
Gradinaru, Daniela
Nitulescu, George Mihai
author_sort Nitulescu, Georgiana
collection PubMed
description SIMPLE SUMMARY: Antimicrobial resistance is spreading globally, making healthcare specialists fear “a return to the dark age of medicine”. Great efforts are being made to develop new antimicrobials or to repurpose discontinued or shelved drugs to be used against resistant “superbugs”. Resistance occurs partly because the antibiotics we use kill the bacteria. However, this also induces a high selection pressure: a resistant bacterium will multiply, while its non-resistant competitors will die. Thus, resistance will develop rapidly in the presence of that antibiotic. An alternative is simply disarming bacteria—reducing their ability to infect the host. In other words, we should develop drugs that inhibit bacterial virulence rather than bacterial viability. Bacterial virulence factors such as collagenases emerged as attractive targets for overcoming antimicrobial resistance. Microbial collagenases digest host collagen, ensuring the spread of the pathogen and its toxins into host tissues. In this study, we aimed to identify plant-derived and repurposed drugs which potently inhibit collagenase A. We achieved this by performing extensive screening. We identified capsaicin, 4′,5-dihydroxyflavone, curcumin, dihydrorobinetin, palmatine chloride, biochanin A, 2′-hydroxychalcone, and juglone as promising collagenase inhibitors. Our data indicate these molecules could be used against infections caused by multi-drug-resistant bacterial pathogens which express collagenase A. ABSTRACT: Bacterial virulence factors are mediating bacterial pathogenesis and infectivity. Collagenases are virulence factors secreted by several bacterial stains, such as Clostridium, Bacillus, Vibrio and Pseudomonas. These enzymes are among the most efficient degraders of collagen, playing a crucial role in host colonization. Thus, they are an important target for developing new anti-infective agents because of their pivotal roles in the infection process. A primary screening using a fluorescence resonance energy-transfer assay was used to experimentally evaluate the inhibitory activity of 77 compounds on collagenase A. Based on their inhibitory activity and chemical diversity, a small number of compounds was selected to determine the corresponding half maximal inhibitory con-centration (IC50). Additionally, we used molecular docking to get a better understanding of the enzyme–compound interaction. Several natural compounds (capsaicin, 4′,5-dihydroxyflavone, curcumin, dihydrorobinetin, palmatine chloride, biochanin A, 2′-hydroxychalcone, and juglone) were identified as promising candidates for further development into useful anti-infective agents against infections caused by multi-drug-resistant bacterial pathogens which include collagenase A in their enzymatic set.
format Online
Article
Text
id pubmed-9781087
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-97810872022-12-24 Discovery of New Microbial Collagenase Inhibitors Nitulescu, Georgiana Mihai, Dragos Paul Zanfirescu, Anca Stan, Miruna Silvia Gradinaru, Daniela Nitulescu, George Mihai Life (Basel) Article SIMPLE SUMMARY: Antimicrobial resistance is spreading globally, making healthcare specialists fear “a return to the dark age of medicine”. Great efforts are being made to develop new antimicrobials or to repurpose discontinued or shelved drugs to be used against resistant “superbugs”. Resistance occurs partly because the antibiotics we use kill the bacteria. However, this also induces a high selection pressure: a resistant bacterium will multiply, while its non-resistant competitors will die. Thus, resistance will develop rapidly in the presence of that antibiotic. An alternative is simply disarming bacteria—reducing their ability to infect the host. In other words, we should develop drugs that inhibit bacterial virulence rather than bacterial viability. Bacterial virulence factors such as collagenases emerged as attractive targets for overcoming antimicrobial resistance. Microbial collagenases digest host collagen, ensuring the spread of the pathogen and its toxins into host tissues. In this study, we aimed to identify plant-derived and repurposed drugs which potently inhibit collagenase A. We achieved this by performing extensive screening. We identified capsaicin, 4′,5-dihydroxyflavone, curcumin, dihydrorobinetin, palmatine chloride, biochanin A, 2′-hydroxychalcone, and juglone as promising collagenase inhibitors. Our data indicate these molecules could be used against infections caused by multi-drug-resistant bacterial pathogens which express collagenase A. ABSTRACT: Bacterial virulence factors are mediating bacterial pathogenesis and infectivity. Collagenases are virulence factors secreted by several bacterial stains, such as Clostridium, Bacillus, Vibrio and Pseudomonas. These enzymes are among the most efficient degraders of collagen, playing a crucial role in host colonization. Thus, they are an important target for developing new anti-infective agents because of their pivotal roles in the infection process. A primary screening using a fluorescence resonance energy-transfer assay was used to experimentally evaluate the inhibitory activity of 77 compounds on collagenase A. Based on their inhibitory activity and chemical diversity, a small number of compounds was selected to determine the corresponding half maximal inhibitory con-centration (IC50). Additionally, we used molecular docking to get a better understanding of the enzyme–compound interaction. Several natural compounds (capsaicin, 4′,5-dihydroxyflavone, curcumin, dihydrorobinetin, palmatine chloride, biochanin A, 2′-hydroxychalcone, and juglone) were identified as promising candidates for further development into useful anti-infective agents against infections caused by multi-drug-resistant bacterial pathogens which include collagenase A in their enzymatic set. MDPI 2022-12-15 /pmc/articles/PMC9781087/ /pubmed/36556479 http://dx.doi.org/10.3390/life12122114 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Nitulescu, Georgiana
Mihai, Dragos Paul
Zanfirescu, Anca
Stan, Miruna Silvia
Gradinaru, Daniela
Nitulescu, George Mihai
Discovery of New Microbial Collagenase Inhibitors
title Discovery of New Microbial Collagenase Inhibitors
title_full Discovery of New Microbial Collagenase Inhibitors
title_fullStr Discovery of New Microbial Collagenase Inhibitors
title_full_unstemmed Discovery of New Microbial Collagenase Inhibitors
title_short Discovery of New Microbial Collagenase Inhibitors
title_sort discovery of new microbial collagenase inhibitors
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9781087/
https://www.ncbi.nlm.nih.gov/pubmed/36556479
http://dx.doi.org/10.3390/life12122114
work_keys_str_mv AT nitulescugeorgiana discoveryofnewmicrobialcollagenaseinhibitors
AT mihaidragospaul discoveryofnewmicrobialcollagenaseinhibitors
AT zanfirescuanca discoveryofnewmicrobialcollagenaseinhibitors
AT stanmirunasilvia discoveryofnewmicrobialcollagenaseinhibitors
AT gradinarudaniela discoveryofnewmicrobialcollagenaseinhibitors
AT nitulescugeorgemihai discoveryofnewmicrobialcollagenaseinhibitors